Presentatie - vzw farmaka asbl
Presentatie - vzw farmaka asbl
Presentatie - vzw farmaka asbl
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Consensusvergadering angor 2006. Discussion of CAPRIE study 1996.<br />
Design N/n Population Sd Interventions Outcomes Results<br />
RCT n=19<br />
185<br />
-History of<br />
stroke, MI<br />
or<br />
peripheral<br />
vascular<br />
disease<br />
2y -Clopidogrel 75<br />
mg<br />
-ASA 325 mg<br />
Anti-aggregantia<br />
Primary<br />
composite<br />
endpoint: stroke,<br />
MI or CV death<br />
Gastro-intestinal<br />
bleeding<br />
Skin rash<br />
5.32% (clopidogrel) vs 5.83%<br />
RRR= 8.7 (95%CI 0.3 to 16.5)<br />
NNT/2j=200<br />
Verschil enkel statistisch significant in subgroep<br />
met perifeer arterieel lijden. In subgroepen AMI en<br />
CVA was het verschil niet significant<br />
Higher with ASA<br />
- Patients ever reporting: 1.99 vs 2.66% (p
Change language